Diabetic Retinopathy Drug Market Share

  • Report ID: 99
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Diabetic Retinopathy Industry - Regional Synopsis

North America Market Statistics

Regionally, the diabetic retinopathy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America industry is estimated to account for largest revenue share by 2037, driven by supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure, and allocation of substantial healthcare expenditure by government., driven by supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure, and allocation of substantial healthcare expenditure by government. In addition to this, Europe is the second largest shareholder in the market attributing to the increasing obese population in the region, who are prone to diabetes and other related vision disorders. It is calculated that around 3-4% of Europeans are diagnosed with diabetic retinopathy every year.

APAC Market Analysis

Moreover, the market in Asia Pacific is predicted to witness a notable growth during the forecast period as a result of a huge patient pool, growing elderly populace and the rise in innovations for treatment of diabetic retinopathy. The growth of the market in this region is expected to be steered majorly by nations such as China and Japan owing to the escalating per capita income and significant developments in the medical sector.

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of diabetic retinopathy is estimated at USD 10.01 billion.

Diabetic Retinopathy Market size was valued at USD 9.49 billion in 2024 and is set to exceed USD 21.52 billion by 2037, expanding at over 6.5% CAGR during the forecast period i.e., between 2025-2037.

North America industry is estimated to account for largest revenue share by 2037, driven by supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure, and allocation of substantial healthcare expenditure by government.

The major players in the market are Pfizer Inc. Bayer AG, Abbott Laboratories, Novartis AG, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos